The results highlighted the strength of GSK's underlying business driven by HIV and vaccines, Dani Saurymper, a portfolio manager at Pacific Asset Management, and a GSK shareholder, said.īut without an update on the Zantac litigation or change in pipeline outlook, the shares may continue to lag peers, he said.Gardenscapes was one of the most-played games on Facebook. He said he hoped to hear more on the company's preparations for the RSV vaccine debut. GSK shareholder Markus Manns, senior portfolio manager at Union Investment, said the new guidance was expected after a strong first quarter. RSV is a leading cause of pneumonia in toddlers and the elderly, causing thousands of hospitalisations and deaths each year. ![]() The Arexvy-branded RSV shot was approved by U.S. ![]() launch in the autumn of the company's inoculation against respiratory syncytial virus (RSV), which GSK hopes will be its next blockbuster drug, though initial sales would not grow as rapidly as Shingrix, Walmsley said. The results come ahead of the much-anticipated U.S. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion).Īnalysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |